<DOC>
	<DOCNO>NCT00211965</DOCNO>
	<brief_summary>Staphylococcus aureus ( S. aureus ) common pathogen encounter infection associate orthopedic surgery . StaphVAXÂ® bivalent S. aureus type 5 8 vaccine contains purify capsular polysaccharide implicate major factor invasiveness S. aureus . Immunoprophylaxis vaccinate S. aureus prior surgery could provide sufficient antibody concentration surgery wound heal period decrease risk S. aureus infection . This study aim demonstrate immunogenicity safety single dose StaphVAX patient candidate orthopedic surgery .</brief_summary>
	<brief_title>StaphVAX Immunogenicity Safety Orthopaedic Joint Surgery</brief_title>
	<detailed_description />
	<mesh_term>Staphylococcal Infections</mesh_term>
	<criteria>Age 18 year old Candidate knee hip replacement Expectation protocol compliance Negative pregnancy test , appropriate Known S. aureus infection prior 3 month Infection prior 2 week Known HIV infection Immunomodulatory drug Malignancy ( basal cell squamous cell carcinoma , carcinoma situ cervix , early prostate cancer ) Hypersensitivity component StaphVAX</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Knee replacement surgery</keyword>
	<keyword>hip replacement surgery</keyword>
	<keyword>nosocomial infection</keyword>
	<keyword>Arthroplasty</keyword>
</DOC>